ZMIZ1 (Zinc Finger MIZ-Type Containing 1) is a protein encoded by the ZMIZ1 gene, belonging to the PIAS (Protein Inhibitor of Activated STAT) family. It functions as a transcriptional coactivator, interacting with various signaling pathways, including TGF-β, Wnt, and androgen receptor (AR)-mediated signaling. ZMIZ1 contains a conserved MIZ (MIZUCHI) domain and a proline-rich region, enabling its role in regulating transcription, protein-protein interactions, and post-translational modifications. Studies link ZMIZ1 to cell proliferation, differentiation, and apoptosis, with implications in cancer, immune disorders, and neurodevelopmental conditions.
ZMIZ1 antibodies are immunological tools designed to detect and study the expression, localization, and functional roles of ZMIZ1 in biological systems. These antibodies are commonly used in techniques like Western blotting, immunohistochemistry (IHC), immunofluorescence (IF), and co-immunoprecipitation (Co-IP). They help researchers investigate ZMIZ1's involvement in diseases, such as its overexpression in certain cancers (e.g., breast, prostate) or its regulatory role in autoimmune diseases. Some antibodies target specific epitopes or post-translationally modified forms of ZMIZ1. enabling detailed mechanistic studies. Validation via knockout/knockdown models or recombinant protein controls is critical to ensure specificity. Commercial ZMIZ1 antibodies are available from multiple suppliers, often developed in hosts like rabbits or mice, with varying clonal properties (monoclonal/polyclonal). Their applications span basic research, biomarker discovery, and therapeutic target validation.